WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 06-Sep-2017 (data as of 05-Sep-2017)
Next overall update 2018
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 52'0901 Infant (under 12 months) mortality rate: 22
GDP / capita (US$): 85'2091 Child (under 5 years) mortality rate: 32

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 5'622  5'535  5'448  5'361  5'271  3'914  3'013  2'412 
Births 50  50  49  49  49  50  55  40 
Surviving infants 50  50  49  49  49  50  55  40 
Pop. less than 5 years 265  264  264  264  264  256  228  194 
Pop. less than 15 years 857  858  863  868  873  840  647  652 
Female 15-49 years 1'424  1'419  1'416  1'412  1'406  1'128  936  694 

Number of reported cases

(Click for retrospective incidence data for Singapore)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  138  42  141  143 
Mumps
ChartChart
  495  521  5'981 
Pertussis
ChartChart
  17  24 
Polio*
ChartChart
 
Rubella
ChartChart
  48  64  312 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Singapore)
Vaccine year result method % card seen                                                
BCG          99  99  99  99  99  99  99  85 
DTP1          98  98  98  98  98  98 
DTP3          97  96  96  97  97  98  85  84 
DTP4          90  90 
IPV1          98  98 
HepB_BD          91  71  68  68  67  72 
HepB3          96  96  96  97  97  97  74 
Hib3          96  96  86  85 
JapEnc         
MCV1          95  95  95  95  95  96  84  47 
MCV2          88  90  90  90  90  98 
MenA         
PCV1          84  79  72  64 
PCV2          83  76  69  60 
PCV3          78  75  69  60  52 
Pol3          96  96  96  97  97  98  85  83 
Rota1          58 
RotaC          57 
RCV1         
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Singapore)
BCG
ChartChart
  99  99  99  99  99  99  99  85 
DTP1
ChartChart
  98  98  98  98  98  98  95  94 
DTP3
ChartChart
  97  96  96  97  97  98  85  84 
HepB3
ChartChart
  96  96  96  97  97  97  74 
HepB_BD
ChartChart
  71  71  68  68  67 
Hib3
ChartChart
  96  96  86  85 
MCV1
ChartChart
  95  95  95  95  95  96  84  47 
MCV2
ChartChart
  88  90  90  90  90  98 
PCV3
ChartChart
  78  75  69  60  52 
Pol3
ChartChart
  96  96  96  97  97  98  85  83 
RCV1
ChartChart
  95  95  95  95  95  96  84 
RotaC
ChartChart
  57  57 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTaP 3, 4, 5, 18 months;
HepB birth; 1, 5-6 months; Yes
HPV 9-26 (x3 doses); Yes females only
MMR 12, 15-18 months; Yes
OPV 3, 4, 5, 18 months; 6-7, 10-11 years; Yes
Pneumo_conj 3, 5, 12 months; Yes
Pneumo_ps Yes high risk groups
Tdap 10-11 years; Yes

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number       Refer to 6010       
Nº of districts with microplans that include activities to raise immunization coverage number   NA  NA    NA  NA  NA 

System performance

Total Nº districts in country number   NA      NA  NA  NA 
Nº districts with measles (MCV1) coverage >=95% number   NA  NA    NA  NA  NA 
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND   Yes  Yes  Yes  Yes  Yes  No 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR   Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.